Genocea Financial Statements From 2010 to 2024
| GNCADelisted Stock | USD 0.0002 0.0001 100.00% |
Check Genocea Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genocea Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Genocea financial statements analysis is a perfect complement when working with Genocea Biosciences Valuation or Volatility modules.
Genocea |
Genocea Biosciences Company Operating Margin Analysis
Genocea Biosciences' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Genocea Biosciences Operating Margin | (29.59) % |
Most of Genocea Biosciences' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genocea Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Genocea Biosciences has an Operating Margin of -29.5887%. This is 15.65% lower than that of the Biotechnology sector and 73.6% lower than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Genocea Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genocea Biosciences's current stock value. Our valuation model uses many indicators to compare Genocea Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genocea Biosciences competition to find correlations between indicators driving Genocea Biosciences's intrinsic value. More Info.Genocea Biosciences is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genocea Biosciences' earnings, one of the primary drivers of an investment's value.About Genocea Biosciences Financial Statements
Genocea Biosciences stakeholders use historical fundamental indicators, such as Genocea Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Genocea Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genocea Biosciences' assets and liabilities are reflected in the revenues and expenses on Genocea Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genocea Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Genocea Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 74 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Genocea Stock
If you are still planning to invest in Genocea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genocea Biosciences' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance |